PEAK PROCESSING LIMITED — Capital/Financing Update 2021

Jun 22, 2021

==> picture [596 x 149] intentionally omitted <==

ASX Announcement | 23 June 2021 Althea Group Holdings (ASX:AGH)

Althea enters the USD$667M South African cannabis market

Investment Highlights:

• Althea has exported from Australia its first commercial shipment of products destined for sale in the emerging South African medicinal cannabis market

• South Africa represents a large opportunity for the Company, with the legal medicinal cannabis industry estimated to be worth approximately USD$667 million by 2023[1]

• Althea is one of the world’s leading cannabis-based medicine brands, with sizeable market share across Australia, the United Kingdom and Germany

23 June 2021: Althea Group Holdings Limited (ASX:AGH) (‘Althea’ or ‘the Company’) , a global leader in the manufacturing, sales and distribution of pharmaceutical cannabis products and cannabis-based consumer packaged goods, is pleased to announce that is has completed its first shipment of Althea medicinal cannabis products to the Company’s local partner in South Africa, Africann (Pty) Ltd (‘Africann’).

This first shipment of Althea products set for sale in South Africa is a major achievement for the Company. The initial shipment provides Althea with an early mover advantage in the emerging South African medicinal cannabis industry, which is estimated to be worth approximately USD$667 million by 2023[1] .

Althea’s exclusive distributor in the country, Africann, is a licensed cannabis wholesaler specialising in the import and distribution of medicinal cannabis products in South Africa.

Althea CEO, Joshua Fegan said: “We are excited to have exported our initial shipment of Althea products for South Africa. This development once again reflects our ambition and progress in becoming the world’s leading supplier of cannabis-based medicines. The Althea brand continues to build trust and enduring loyalty with Healthcare Professionals and patients all over the globe, with South Africa the latest country able to experience our unrivalled market access program.”

-ENDS-

Authorised by: Robert Meissner, Company Secretary

1 Source: Prohibition Partners, The African Cannabis Report, 2019, page 42.

==> picture [596 x 92] intentionally omitted <==

==> picture [596 x 149] intentionally omitted <==

For further information, please contact:

Althea Media Enquiries Investor Relations Josh Fegan Dan Francome Julia Maguire CEO & Managing Director Media Relations Investor Relations Partner M: 1300 70 20 20 P: 1300 70 20 20 P: +61 02 8999 3699 E: contact@althea.life E: dfrancome@althea.life E: julia@thecapitalnetwork.com.au

About Althea Group Holdings Limited (ASX:AGH)

Althea Group Holdings Ltd (ASX:AGH) is a global leader in the manufacturing, sales and distribution of pharmaceutical cannabis products and cannabis-based consumer packaged goods. Althea also offers a range of education, access and management services to support eligible patients and Healthcare Professionals in navigating medicinal cannabis treatment pathways.

Althea operates in highly regulated and legal cannabis markets across the world with burgeoning operations in Europe, North America, Australia and Africa.

To learn more, please visit: www.althea.life

==> picture [596 x 92] intentionally omitted <==